There are currently 192 clinical trials in Sarasota, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Florida Cancer Specialists, Sarasota Memorial Hospital, GSK Investigational Site and Sarasota Retina Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of PYX-201 in Solid Tumors
Recruiting
The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with relapsed/refractory (R/R) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: SCRI - Florida Cancer Specialists, Sarasota, Florida
Conditions: Solid Tumor, Advanced Solid Tumor
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
Recruiting
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Repair System in patients with symptomatic severe tricuspid regurgitation who have been determined to be at an intermediate or greater estimated risk of mortality with tricuspid valve surgery by the cardiac surgeon with concurrence by the local Heart Team
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Sarasota Memorial Health Care System, Sarasota, Florida
Conditions: Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease
A Study of ASP1570 Alone or in Combination With Pembrolizumab or Standard Therapies in Adults With Solid Tumors
Recruiting
Immune therapies work with the body's immune system to treat a number of cancers. They work with T-cells, a type of white blood cell, to target and attack specific tumors. However, some tumors can become resistant to attack by T-cells over time. They do this by sending "off" signals to T-cells. The researchers are finding ways to switch the T-cells back on. Before a treatment can be approved for use, clinical studies need to be done. This study will provide more information on ASP1570 in adults... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Florida Cancer Specialist & Research Institute Sarasota, Sarasota, Florida
Conditions: Advanced Solid Tumors
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
Recruiting
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible impact on the disease progression of PBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Covenant Research and Clinics, LLC, Sarasota, Florida
Conditions: Primary Biliary Cholangitis, PBC
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Recruiting
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Florida Cancer Specialists - Sarasota Downtown, Sarasota, Florida +2 locations
Conditions: Endometrial Serous Adenocarcinoma, Uterine Corpus Carcinosarcoma, Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Undifferentiated Carcinoma
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Recruiting
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The participants will be treated with either zasocitinib, active comparator, or placebo. Participants will be in the study for up to 60 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Sarasota Arthritis Research Center, Sarasota, Florida
Conditions: Psoriatic Arthritis
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Recruiting
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: Not set, Sarasota, Florida
Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/29/2025
Locations: Akero Clinical Study Site, Sarasota, Florida
Conditions: NASH With Fibrosis, MASH With Fibrosis
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Recruiting
This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Florida Cancer Specialists, Sarasota, Florida
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Recruiting
A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Dren Investigational Site, Sarasota, Florida
Conditions: Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Castrate Resistant Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Head-and-neck Squamous Cell Carcinoma, Endometrial Cancer, Ovarian Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Urothelial Carcinoma
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
Recruiting
CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Florida Cancer Specialists, Sarasota, Florida
Conditions: Advanced Solid Tumor, NSCLC
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
Recruiting
This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension (OLE). The purpose of the core period (52 weeks of treatment) of this study is to evaluate the efficacy, safety, and tolerability of remibrutinib (LOU064) vs. placebo in adults suffering from CINDU inadequately controlled by H1-antihistamines (H1-AHs). The purpose of the OLE period is to collect long-term efficacy, safety, and tolerability data o... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/28/2025
Locations: Sarasota Clinical Research, Sarasota, Florida
Conditions: Chronic Inducible Urticaria